| Today’s Big NewsJan 2, 2025 |
| By Nick Paul Taylor Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. |
|
|
|
By Zoey Becker The buyout spells the end of Marinus' review of strategic alternatives following two key phase 3 misses and scrapped expansion efforts for its approved seizure med Ztalmy. |
By Andrea Park Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on Novo Nordisk’s early lead in the obesity market. |
By Conor Hale Abbott and Dexcom have agreed to settle all of their remaining international legal disputes over patents related to their continuous glucose monitors for people with diabetes. |
By Angus Liu More than three years after Novartis’ plan for a speedy approval for its intrathecal Zolgensma was thwarted by an FDA requirement for a phase 3 trial, the company is back with a positive readout from that study, which could give the gene therapy a much-needed boost. |
By Kevin Dunleavy Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. In 2024, the FDA gave a thumbs-up to more than xx new treatments, which was down from 60-plus new drugs in 2023. |
By Nick Paul Taylor Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for antibody-drug conjugates and other assets in the final few days of 2024. |
By Fraiser Kansteiner Drugmakers plan to raise U.S. list prices on some 250 branded drugs beginning this month, Reuters reports, citing data from healthcare research firm 3 Axis Advisors. Notable medicines subject to price increases include Pfizer’s COVID-19 drug Paxlovid, Bristol Myers Squibb’s CAR-T therapies Abecma and Breyanzi and a clutch of vaccines from Sanofi. |
By Ben Adams Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new antibody-drug conjugate asset to its pipeline. |
By Andrea Park Currax Pharmaceuticals is kicking off the new year with a new direct-to-consumer campaign for its weight loss medication Contrave. |
By Nick Paul Taylor Neumora Therapeutics’ big bet on a new era of neuroscience has delivered an age-old result. The first of three late-stage readouts on Neumora’s lead drug candidate has ended in failure, wiping more than 80% off the value of the biotech. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Gabrielle Masson CARsgen Therapeutics’ CAR-T improved progression-free survival (PFS) compared to approved therapies for patients with advanced stomach cancer in a phase 2 trial. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees. |
|
|---|
|
|
| |
|
